Screener
Chemours CC Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Chemours in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Chemours’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 11:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001627223-26-000024
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $671 | $670 |
| Restricted cash and restricted cash equivalents | — | 2 |
| Accounts and notes receivable, net | 907 | 679 |
| Inventories | 1,452 | 1,569 |
| Prepaid expenses and other | 63 | 80 |
| Assets held for sale | 1 | 1 |
Item 1. INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Chemours's cash & equivalents?
- Chemours (CC) reported cash & equivalents of $671M in Q2 2026.
- How has Chemours's cash & equivalents changed year-over-year?
- Chemours's cash & equivalents increased by 33.7% year-over-year, from $502M to $671M.
- What is the long-term trend for Chemours's cash & equivalents?
- Over 5 years (2020 to 2025), Chemours's cash & equivalents has grown at a -9.5% compound annual growth rate (CAGR), from $1.11B to $670M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Chemours's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude